

**SAURABH DAHIYA, MD**

Division of Hematology and Oncology,  
Department of Internal Medicine, Baystate  
Medical Center, Tufts University School of  
Medicine, Springfield, MA

**MANMEET S. AHLUWALIA, MD<sup>a</sup>**

The Rose Ella Burkhardt Brain Tumor Neuro-  
Oncology Center, Solid Tumor Oncology, Taussig  
Cancer Institute, Cleveland Clinic; Neurological  
Institute, Cleveland Clinic; Assistant Professor  
of Medicine, Cleveland Clinic Lerner College of  
Medicine of Case Western Reserve University,  
Cleveland, OH

**HARNEET K. WALIA, MD**

Center for Sleep Disorders, Neurological Institute,  
Cleveland Clinic; Assistant Professor of Family Medicine,  
Cleveland Clinic Lerner College of Medicine of Case  
Western Reserve University, Cleveland, OH

# Sleep disturbances in cancer patients: Underrecognized and undertreated

## ABSTRACT

Sleep-related complaints are extremely common in patients with cancer but often are not recognized, and even if they are, they are seldom treated. Recognizing insomnia in cancer patients is imperative, as appropriate treatment can improve quality of life.

## KEY POINTS

Sleep disturbances, primarily insomnia, profoundly affect all aspects of quality of life.

Insomnia can be caused or worsened by a number of other conditions, such as pain, fatigue, depression, and anxiety, and these in turn can be worsened by insomnia.

Cognitive-behavioral therapy is the treatment of choice for chronic insomnia. Underlying problems should be addressed.

Drugs are often prescribed to help cancer patients sleep but should be used with caution, as there is limited information from clinical trials in this population.

**M**ANY CANCER PATIENTS don't sleep well, for a variety of reasons. It is an important problem: not only does poor sleep worsen quality of life, it may affect prognosis. Moreover, treatment is available.

Yet many physicians caring for cancer patients do not ask about sleep problems, underestimating their impact or focusing on more urgent problems. Also, patients may not want to bring up the topic because they consider poor sleep to be unavoidable and untreatable and because they fear that reporting it may shift the focus of their treatment from trying to cure the cancer to easing its symptoms.

This practical review will help health care professionals avoid the common barriers to diagnosis and treatment of poor sleep in cancer patients. Because there are few data on other sleep disorders such as sleep apnea and restless leg syndrome, we will focus on the most common one in cancer patients—insomnia—and its effects on other symptoms and quality of life.

## MORE PATIENTS SURVIVE CANCER NOW

Today, more patients are surviving cancer, but cancer symptoms and the side effects of surgery, chemotherapy, and radiation therapy may persist for years.<sup>1,2</sup> The most common complaints include cancer-related fatigue, leg restlessness, anxiety, insomnia, and excessive sleepiness.<sup>3</sup>

Sleep disturbances appear to contribute to the other problems and are relatively easier to quantify. Most studies of sleep disorders in cancer patients have looked specifically at insomnia,<sup>4</sup> although a few have explored the prevalence of other sleep disorders, such as sleep-disordered breathing and limb movements during sleep.<sup>5</sup>

<sup>a</sup> Dr. Ahluwalia has disclosed serving on an advisory board for Genentech and Roche, teaching and speaking for Merck, and receiving research funding from Novartis.

doi:10.3949/ccjm.80a.12170

The *International Classification of Sleep Disorders*, 2nd edition,<sup>6</sup> defines insomnia as difficulty going to sleep or staying asleep (the latter defined as waking up in the middle of the night, with wakeful episodes lasting more than 30 minutes), early-morning awakenings (waking 30 minutes or more before the intended time), or nonrestorative sleep, causing significant distress or impairment of day-time functioning.

### ■ INSOMNIA WORSENS QUALITY OF LIFE

Insomnia significantly worsens quality of life in cancer patients, and if it can be detected and effectively treated, quality of life is likely to improve. Studies in cancer patients have found that those with insomnia:

- Were less able to cope with stress and carry on their activities of daily living<sup>3</sup>
- Were much less able to function and reported more pain, less energy, and greater difficulty in dealing with emotional problems<sup>7</sup>
- Had poor quality of life, both physically and emotionally.<sup>3,8</sup>

### ■ PERHAPS MORE THAN HALF OF CANCER PATIENTS HAVE INSOMNIA

Depending on the methods used and populations studied, at least 30% and perhaps more than half of patients with cancer have insomnia (TABLE 1).<sup>3,4,8-14</sup> It is one of the most commonly reported complaints in this group,<sup>15-17</sup> and it occurs before, during, and after treatment of cancer.

Although the prevalence may differ in various cancers, it is still higher than in the general population. In a study of about 450 patients with cancer or depression and 300 healthy volunteers, 62% of the cancer patients reported moderate to severe sleep disturbance, compared with 52% of the depressed patients and 30% of the healthy volunteers.<sup>18</sup>

When Davidson et al<sup>3</sup> surveyed nearly 1,000 cancer patients, one-third said they had insomnia. The problem was most prevalent in lung and breast cancer patients.

In a longitudinal study by Savard et al,<sup>13</sup> the prevalence of insomnia declined over time but remained high even at the end of 18 months. It was more prevalent in patients

### Drugs mentioned in this article

Amitriptyline (Elavil)	Modafinil (Provigil)
Chlorpromazine (Thorazine)	Nortriptyline (Pamelor)
Clonazepam (Klonopin)	Olanzapine (Zyprexa)
Diphenhydramine (Benadryl)	Paroxetine (Paxil)
Doxepin (Silenor)	Ramelteon (Rozerem)
Eszopiclone (Lunesta)	Risperidone (Risperdal)
Flurazepam (Dalmane)	Temazepam (Restoril)
Hydroxyzine (Vistaril)	Thioridazine (Mellaril)
Lorazepam (Ativan)	Trazodone (Desyrel)
Methylphenidate (Ritalin)	Zaleplon (Sonata)
Mirtazapine (Remeron)	Zolpidem (Ambien)

with gynecologic and breast cancer than in those with prostate cancer.<sup>13,19</sup>

### ■ SLEEP PROBLEMS ARE UNDERREPORTED

Sleep problems in cancer patients often go unrecognized because patients do not report them. In a survey of 150 patients,<sup>20</sup> 44% reported having had sleep problems during the preceding month. However, only one-third of those with sleep problems told their health care providers. This highlights the need for physicians to address sleep complaints in cancer patients at every visit and, if needed, to refer them to a sleep specialist for further evaluation and management.

**Too often,  
pain is  
inadequately  
controlled**

### ■ INSOMNIA IS OFTEN ASSOCIATED WITH OTHER PROBLEMS

Many things can interfere with sleep in cancer patients: the cancer itself (eg, pain due to tumor invasion), medical treatments (eg, narcotics, chemotherapy, neuroleptics, sympathomimetics, steroids, sedative hypnotics), psychosocial disturbances (eg, depression, anxiety, stress), and comorbid medical issues.

In this population, insomnia is often part of a cluster of symptoms that includes pain, fatigue, depression, and anxiety. These act synergistically, worsening quality of life.<sup>21-24</sup>

### Cancer-related fatigue and insomnia

Cancer-related fatigue is a distressing, persistent, subjective sense of tiredness or ex-

**TABLE 1**

**Selected studies of prevalence of sleep disturbances in cancer patients**

Study	No. of patients	Type of study	Time of assessment	Cancer type	Assessment method	Findings
<b>Davidson, 2002<sup>3</sup></b>	982	Cross-sectional survey	Routine outpatient office visits	Breast, gastro-intestinal, genitourinary, gynecologic, lung, and non-melanoma skin cancers	42-item "Sleep Survey" questionnaire	30% reported insomnia; 22% used tranquilizers
<b>Ancoli-Israel, 2006<sup>10</sup></b>	85	Actigraphy and cross-sectional survey	Before beginning chemotherapy	Stage I–IIIA breast cancer	72-hour actigraphy, PSQI, MFSI-SF, FOSQ, FACT-B, CES-D	Women reported disturbed sleep, with a mean total PSQI score of 7.0
<b>Miaskowski, 2011<sup>11</sup></b>	185	Actigraphy and cross-sectional survey	Before beginning radiation therapy	Breast, prostate, lung, brain	48-hour actigraphy, PSQI, GSDS	More than 56% had a global PSQI score > 5 26% had GSDS above the proposed cutoff of > 8 for oncology patients
<b>Liu, 2012<sup>12</sup></b>	97	Prospective study	Patients undergoing chemotherapy	Newly diagnosed stage I–III breast cancer	Ambulatory actigraphy, PSQI, MFSI-SF	At baseline, 61% of the women reported a PSQI > 5; at the end of treatment, 76% reported a PSQI > 5, and 42% reported a PSQI > 8
<b>Chen, 2008<sup>8</sup></b>	115	Cross-sectional survey	Patients undergoing chemotherapy	Lung	PSQI, EORTC questionnaire	Patients' mean PSQI score for days with chemotherapy was $6.86 \pm 3.83$ ; for days without chemotherapy, the score was $6.23 \pm 3.47$
<b>Savard, 2011<sup>13</sup></b>	962	Prospective longitudinal study	From preoperative visit to 18 months after the surgery	Mixed	Insomnia interview schedule	59% had insomnia at baseline; the prevalence of insomnia generally declined over time but remained pervasive even after 18 months (36%)
<b>Sela, 2005<sup>14</sup></b>	100	Cross-sectional survey	Palliative cancer patients attending a pain and symptom control clinic	Mixed	9-item sleep questionnaire and ESAS	19% reported insomnia before their cancer diagnosis; after diagnosis, 72% did

PSQI = Pittsburgh Sleep Quality Index (interpretation: score  $\leq 5$  associated with good sleep quality, and score  $> 5$  associated with poor sleep quality); MFSI-SF = Multidimensional Fatigue Symptom Inventory–Short Form; FOSQ = Functional Outcome of Sleep Questionnaire; FACT-B = Functional Assessment of Cancer Therapy–Breast; CES-D = Center for Epidemiological Studies–Depression scale; GSDS = General Sleep Disturbance Scale; EORTC = European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30); ESAS = Edmonton Symptom Assessment System

haustion that is related to cancer or cancer treatment, that is not proportional to recent activity and that interferes with usual functioning.<sup>25</sup> It has been reported by up to 90% of cancer patients in some studies.<sup>26–28</sup>

Cancer-related fatigue worsens quality of life and is one of the most distressing and persistent symptoms experienced before, during, and after cancer treatment.<sup>29,30</sup> Furthermore, it can lead to sleep disturbances and daytime somnolence and further aggravate insomnia.<sup>31,32</sup> The two conditions are often reported as part of a cluster of interrelated symptoms that include pain, depression, and loss of concentration and other cognitive functions, suggesting that they may share a common etiology.<sup>33–35</sup>

Åhsberg et al<sup>36</sup> examined different aspects of perceived cancer-related fatigue in patients undergoing radiotherapy and found correlations between lack of energy, sleepiness, and cancer-related fatigue.

Current understanding of the possible link between cancer-related fatigue and insomnia suggests that interventions targeting the insomnia and daytime sleepiness could decrease the fatigue as well.<sup>31</sup>

### **Pain and insomnia in cancer patients**

Pain is reported by 60% to 90% of patients with advanced cancer,<sup>37,38</sup> its intensity usually varying with the extent of disease. Too often, it is inadequately controlled.<sup>39</sup> Furthermore, it is thought to contribute to insomnia.<sup>40</sup>

In a study of more than 1,600 cancer patients, nearly 60% reported insomnia in addition to pain.<sup>41</sup> The severity of pain directly correlated with the probability of insomnia.

Conversely, research suggests that sleep disturbances, primarily insomnia, can increase cancer patients' sensitivity to pain.<sup>42</sup> One hypothesis is that adequate sleep is needed to promote processes relevant to recovery from pain, both physiologic (ie, tissue repair) and psychological (ie, transient cessation of the perception of pain signals).<sup>43</sup>

### **Paradoxically, opioids can worsen insomnia**

Cancer pain is often treated with opioids, which, paradoxically, can cause or worsen insomnia.

Although opioids induce sleep, they also depress respiration, and at night, they can cause or worsen sleep-disordered breathing (obstruc-

tive or central sleep apnea or ataxic breathing), leading to episodes of hypoxia, arousals, and fragmented sleep.<sup>44</sup> Moreover, opioids can lead to daytime sedation. Further, psychostimulants such as methylphenidate, given to counteract opioid-induced sedation, can cause anxiety and insomnia. Thus, the interaction between cancer-related pain, insomnia, and pain management leads to a vicious cycle. Understanding this process, we can try to break the cycle and help patients with cancer sleep better.

However, how best to treat sleep-disordered breathing in patients taking opioids long-term is not well established.

In general, the primary intervention is to reduce the opioid dose. Practitioners should continually assess the need for these drugs and consider referral to a drug-behavior treatment center to help with discontinuation of opioid use when deemed medically appropriate.<sup>45</sup> Other strategies include positive airway pressure ventilation including continuous positive airway pressure, bilevel pressure devices with backup rate, or adaptive servoventilators. In some cases oxygen supplementation may be required.

Sleep-disordered breathing, when recognized and diagnosed, should be managed in partnership with a sleep specialist.

### **Depression and insomnia in cancer patients**

By some estimates, up to half of cancer patients suffer from depression at some point in their illness.<sup>28</sup> And not without reason: these patients face uncertainty about their life, and this often results in depression or anxiety.<sup>46</sup>

Many cancer patients with depression also have insomnia.<sup>28</sup> Indeed, patients with persistent insomnia are at greater risk of developing psychological disorders such as depression and anxiety.<sup>47</sup>

In a survey of cancer patients, insomnia symptoms were more often attributed to thoughts or concerns about health, family, friends, the cancer diagnosis, and finances than to the actual physical effects of cancer.<sup>48</sup>

## **■ CANCER TREATMENT AND INSOMNIA**

Many cancer patients experience sleep disturbances even before starting treatment.<sup>49</sup> Liu et al<sup>50</sup> showed that, in 76 women about to undergo chemotherapy for breast cancer, those who already had sleep disturbances, fatigue,

**Cancer patients who can't sleep are more sensitive to pain**

TABLE 2

**Cancer treatment as a cause of insomnia**

Cancer treatment	Mechanism of sleep disturbance	Examples
<b>Chemotherapy</b>	Cancer-related fatigue, daytime sleepiness, mood disorders, restless leg syndrome	Taxanes, platinum-based chemotherapy
<b>Radiation therapy</b>	Daytime sleepiness, radiation-induced emesis causing difficulty sleeping, fatigue	
<b>Hormonal therapy</b>	Hot flashes, night sweats, menopause-like symptoms, anxiety	Antiandrogens (eg, leuprolide acetate, flutamide), antiestrogens (eg, tamoxifen)
<b>Biological therapy</b>	Daytime fatigue, malaise	Interferons for malignant melanoma
<b>Corticosteroids</b>	Increase in serum cortisol	Prednisone, dexamethasone
<b>Bone marrow transplantation</b>	Severe anemia causing daytime fatigue and restless leg syndrome	
<b>Surgery</b>	Pain, recovery from surgery, surgery with aesthetic or functional impairments	Mastectomy, debulking surgeries

and depression had more problems, and more severe problems, during chemotherapy.

Radiation therapy and chemotherapy have been reported to cause or precipitate insomnia (TABLE 2).<sup>8,13</sup>

Hormonal therapy and biological therapy can also cause or worsen preexisting insomnia.<sup>51,52</sup> For example, androgen deprivation therapy for prostate cancer and hormonal therapy for breast cancer are often associated with sleep problems.<sup>49,50</sup> Possible mechanisms of insomnia include hot flashes, night sweats, and anxiety caused by such treatments. Biological agents such as interferons, interleukins, and tumor necrosis factor (TNF) alpha, which are often used to treat malignant melanoma, can affect the sleep-wake cycle, leading to insomnia.<sup>53</sup>

Corticosteroids sharply raise serum cortisol levels, which can lead to insomnia. Cancer patients receiving dexamethasone to prevent radiation-induced emesis experienced more insomnia than patients who did not receive dexamethasone.<sup>54</sup>

### ■ IMMUNOLOGIC BASIS OF INSOMNIA IN CANCER PATIENTS

Cancer cells produce inflammatory cytokines

such as interleukin 1 (IL-1), interleukin 6 (IL-6), and TNF alpha, and inflammation plays a role in tumor progression and possibly tumorigenesis.<sup>55</sup>

Specific cytokines also help regulate the sleep-wake cycle. Levels of IL-6 and TNF alpha peak during sleep, and daytime IL-6 levels are inversely related to the amount of nocturnal sleep.<sup>56</sup> Vgontzas et al<sup>57</sup> showed that although mean levels of 24-hour IL-6 and TNF alpha secretion were not significantly different in patients with insomnia vs healthy controls, chronic insomnia was associated with a shift in IL-6 and TNF alpha secretion from nighttime to daytime.<sup>57</sup>

Cancer and its treatment can affect secretion of the cytokines that play a role in the sleep-wake cycle. Thus, the sleep disturbances associated with cancer may also be related to the abnormalities in cytokine levels caused by either cancer or its treatment.

Mills et al<sup>58</sup> found that inflammatory markers such as vascular endothelial growth factor and soluble intercellular adhesion molecule-1 were significantly elevated during chemotherapy in breast cancer patients, and the elevated vascular endothelial growth factor levels were associated with poorer sleep during treatment.

Further research is warranted to establish causality, to help us understand the mecha-

**Opioid-induced sleep-disordered breathing should be managed in partnership with a sleep specialist**



nisms of insomnia and other cancer symptoms, and to develop new treatments for these complaints.

### ■ POOR SLEEP AND CANCER RISK AND OUTCOMES

Sleep disturbances have negative health consequences in cancer. Their impact ranges from plausible carcinogenesis to affecting the course of the disease and cancer survival.

#### Poor sleep and risk of cancer

Epidemiologic studies have examined a possible link between circadian rhythm disruption and breast cancer risk, using both direct measures such as melatonin levels and indirect measures such as sleep duration and shift work. (Melatonin production is related to sleep duration, and night-shift work leads to disruption of sleep pattern and quality of sleep, thus lowering melatonin levels.<sup>59</sup>)

The findings were mixed. Breast cancer risk was significantly and inversely associated with urinary melatonin levels (6-sulfatoxymelatonin) in the Nurses' Health Study II,<sup>60</sup> but not in the Guernsey III study in the United Kingdom.<sup>61</sup> Breast cancer risk was significantly lower with longer sleep duration in Finnish women<sup>62</sup> and in Chinese women in Singapore,<sup>63</sup> but not in American women.<sup>64,65</sup> Results of three cohort studies<sup>66-68</sup> and two case-control studies<sup>69,70</sup> suggested a higher breast cancer risk in women who work evening or overnight shifts. Shorter sleep duration was associated with a higher risk of colorectal adenomas.<sup>71</sup>

These studies make a strong case for an association of cancer with circadian rhythm disruption and shorter sleep duration, possibly from an effect on melatonin levels. However, one should be cautious in interpreting epidemiologic studies: although they show sleep disturbances to be associated with cancer risk, they do not establish causality.

#### Insomnia and cancer outcomes

Evidence is growing that sleep disturbances may affect compliance with treatment, immune function, and outcomes—including survival—in cancer patients.<sup>23,24</sup>

In patients newly diagnosed with various types of cancer, Degner and Sloan<sup>72</sup> showed

that those who suffered from insomnia, nausea, poor appetite, and pain had a lower survival rate at 5 years, independent of the cancer stage. However, no separate analyses were performed to examine the specific influence of insomnia on cancer survival.

Thompson and Li<sup>73</sup> analyzed data from 101 breast cancer patients with available Oncotype DX recurrence scores (a proprietary genetic test performed on tumor tissue that predicts the likelihood of recurrence). The scores were strongly correlated with average hours of sleep per night before breast cancer diagnosis, with fewer hours of sleep associated with a higher (worse) score.

Since these studies were retrospective and merely suggest associations, prospective studies, using more standardized questionnaires and objective measures, are needed to establish causality and to further our understanding of the mechanisms involved.

### ■ HELPING CANCER PATIENTS SLEEP BETTER

Insomnia is generally diagnosed with a thorough history that includes sleep, medical issues, substance use, and psychiatric issues. The sleep history should include specific insomnia-related complaints, presleep conditions and habits, sleep-wake habits, other sleep-related symptoms, and daytime consequences. To obtain the information, one can use questionnaires, sleep logs, psychological screening tests, and bed-partner interviews.<sup>74</sup>

Managing insomnia involves both pharmacologic and nonpharmacologic treatment. It is also important to treat the associated disorders such as depression and anxiety disorders that often accompany insomnia. Long-term management of cancer patients should not be limited to surveillance of cancer but should also involve aggressive treatment of clusters of symptoms such as insomnia, cancer-related fatigue, and pain to yield better long-term quality of life.<sup>75-77</sup>

#### Nonpharmacologic treatment: Cognitive-behavioral therapy

Nonpharmacologic interventions use psychological and behavioral therapies. The American Academy of Sleep Medicine guidelines

**Managing insomnia involves both pharmacologic and nonpharmacologic treatment**

TABLE 3

**Major components of nonpharmacologic therapy for insomnia**

Therapy	Objective	How to practice
<b>Stimulus control</b>	Associate the bed and bedroom with sleep Establish a consistent sleep-wake schedule	Limit activities in bed Go to bed only when sleepy Get out of bed if unable to sleep in 15–20 minutes and do something relaxing
<b>Cognitive-behavioral therapy</b>	Alter the patient's irrational and negative beliefs and attitudes about sleep	Cognitive therapy aims at changing the irrational beliefs relating to sleep and reframe it into more appropriate thoughts; usually prescribed by a psychotherapist Behavior therapy includes stimulus control, sleep restriction, and sleep hygiene education
<b>Relaxation training</b>	Reduce somatic tension and thoughts that prevent the patient from sleeping	Progressive muscle relaxation (the patient can learn to relax one muscle at a time until the entire body is relaxed)
<b>Sleep restriction</b>	Improving sleep efficiency	Restrict the time spent in bed to the actual amount of time spent asleep, then gradually increase the sleep time as sleep efficiency improves
<b>Paradoxical intention</b>	Eliminate the performance anxiety limited to sleep-initiation insomnia	The patient is instructed to stay awake and to avoid any efforts to fall asleep
<b>Biofeedback</b>	Reduce somatic arousal	Visual or auditory feedback

INFORMATION OBTAINED FROM MORGENTHALER T, KRAMER M, ALESSI C, ET AL. PRACTICE PARAMETERS FOR THE PSYCHOLOGICAL AND BEHAVIORAL TREATMENT OF INSOMNIA: AN UPDATE. AN AMERICAN ACADEMY OF SLEEP MEDICINE REPORT. SLEEP 2006; 29:1415–1419.

recommend cognitive behavioral therapy for all patients with insomnia, either alone or in combination with hypnotic medications.

Cognitive-behavioral therapy for insomnia includes various components that help the patient learn coping skills and ways to prevent or mitigate the severity of future episodes (TABLE 3). Various randomized controlled trials found it to be effective for treating insomnia in the general population.<sup>77–79</sup>

Several studies found that cognitive-behavioral therapy for insomnia was effective in cancer patients, not only improving sleep quality but also decreasing psychological distress, resulting in better overall quality of life.<sup>80,81</sup>

Savard et al<sup>81</sup> conducted a randomized controlled trial of cognitive-behavioral therapy for insomnia in 57 patients with breast cancer, examining subjective and objective sleep measures, psychological functioning, quality of life, and immunologic responses.

They found significant improvements in sleep efficiency, mood, quality of life, depression, anxiety, and need for sleep medications. Improvements in subjective sleep measures persisted on 12-month follow-up.

Berger et al,<sup>82</sup> in another randomized controlled trial, assessed behavioral therapy using stimulus control, modified sleep restriction, relaxation therapy, and sleep hygiene in breast cancer patients receiving adjuvant chemotherapy. Behavioral therapy improved sleep quality over time, as measured by the Pittsburgh Sleep Quality Index.

Espie et al<sup>83</sup> evaluated the effect of cognitive-behavioral therapy on prostate, colorectal, gynecologic, and breast cancer patients, with similar results.<sup>83</sup>

Cognitive-behavioral therapy is at least as effective as drug therapy for insomnia in the general population. In the limited studies done in cancer patients, it has been shown to

TABLE 4

**Drugs used for insomnia**

Class	Additional properties	Examples
<b>Nonbenzodiazepine hypnotic agents</b>	Few adverse effects	Zolpidem, zaleplon, eszopiclone
<b>Benzodiazepines</b>	Anxiolytic	Clonazepam, lorazepam
	Hypnotic	Temazepam, flurazepam
<b>Tricyclic antidepressants</b>	Antidepressant	Amitriptyline, nortriptyline
<b>Second-generation antidepressants</b>	Antidepressant and may aid in gaining weight	Trazodone, mirtazapine
<b>Other antidepressants</b>	Antidepressant	Doxepin
<b>Antipsychotics</b>	Mood-stabilizing effect	Olanzapine, risperidone
<b>Antihistamines</b>	Antipruritic	Diphenhydramine, hydroxyzine
<b>Psychostimulants</b>	Reduce cancer-related fatigue	Methylphenidate, modafinil
<b>Neuroleptics</b>	Antiemetic	Chlorpromazine, thioridazine
<b>Melatonin agonists</b>	Fewer adverse effects	Ramelteon

be effective irrespective of the type of cancer and is associated with better long-term outcomes. It diminishes the distress associated with early insomnia, can reduce anxiety, and can promote sleep.

A National Institutes of Health conference on insomnia concluded that cognitive-behavioral therapy is at least as effective as medications for brief treatment of chronic insomnia and that its beneficial effects, in contrast to those produced by medications, may last beyond the termination of treatment.<sup>84</sup>

It is important to think about numerous factors when considering options such as cognitive-behavioral therapy, as patients with cancer have different complications that may affect sleep quality, such as cancer-related fatigue, cancer-related depression, psychological reactions to the disease, side effects of treatment, and cancer-related pain. These need to be addressed as well.

If cognitive-behavioral therapy is not available, self-help interventions (eg, written material, videos, television and Internet resources) can be used. These have several advantages over

professionally administered interventions, including greater accessibility, less burden for the patient, and lower cost. Research is under way evaluating this approach in cancer patients.<sup>85</sup>

**Drug therapy**

The focus of therapy should be to treat underlying disorders that may be causing or contributing to insomnia. However, a substantial number of patients may need to be assessed for pharmacotherapy for insomnia.

Sleep problems in the general population are commonly treated with drugs, and most of the recommendations in cancer patients are based on experience in the general population. However, sleep medications should be used cautiously in cancer patients, since to our knowledge there have been no studies of these agents in patients with cancer.

Side effects also need to be considered. For example, sleep medications can profoundly worsen cancer-related fatigue.

**Hypnotics** are often prescribed for cancer patients.<sup>86,87</sup> A study in five major oncology centers showed that about half of the 1,500

**If cognitive-behavioral therapy is not available, self-help interventions—written material, videos, and TV, and Internet resources—can be used**



patients were prescribed at least one psychotropic drug.<sup>86</sup> In this study, hypnotics were the most frequently prescribed drugs, accounting for 48% of total prescriptions, and 44% of the psychotropic prescriptions were written for sleep.

**Benzodiazepine receptor agonists** such as zaleplon, zolpidem, and eszopiclone can be used for problems with falling asleep and staying asleep.<sup>88,89</sup> They are better tolerated than older, long-acting benzodiazepines,<sup>90</sup> which can cause alterations in sleep-cycle architecture or rebound insomnia. The earlier agents can also cause adverse effects such as tolerance, drowsiness, and cognitive impairment.

A National Institutes of Health conference stated that benzodiazepine receptor agonists are efficacious in the short-term management of insomnia and that their adverse effects are much less frequent and severe than those of the benzodiazepines or other sedating drugs.<sup>84</sup> It also stated that all antidepressants, antihistamines (H1 receptor antagonists), and antipsychotics have potentially significant adverse effects that raise concerns about their risk-to-benefit ratio and their suitability as treatment for chronic insomnia.

**Benzodiazepines** are commonly prescribed for insomnia. They increase sleep efficiency, decrease arousals, and increase stage 2 sleep.

**Melatonin receptor agonists** have been approved by the US Food and Drug Administration for treating insomnia. A recent meta-analysis of eight studies in healthy patients showed improvements in subjective and objective sleep outcomes with the use of ramelteon.<sup>91</sup> The dosages primarily used were 4 to 32 mg. However, most of the studies used a dosage of 4 to 8 mg.

**Antidepressants.** Some of the antidepressants are also used for insomnia, but they can cause daytime fatigue.

Mirtazapine was shown to be effective for insomnia and coexistent mood disorder in cancer patients, but larger trials are needed.<sup>92</sup>

A recent clinical trial with secondary data analyses evaluated the effect of paroxetine on insomnia, depression, and fatigue in patients with cancer. Paroxetine significantly reduced insomnia in both depressed and nondepressed patients after 2 to 3 weeks of treatment.<sup>93</sup>

**TABLE 4** summarizes classes of drugs used for insomnia and their additional therapeutic properties.

## REFERENCES

- Ness KK, Wall MM, Oakes JM, Robison LL, Gurney JG. Physical performance limitations and participation restrictions among cancer survivors: a population-based study. *Ann Epidemiol* 2006; 16:197–205.
- Deimling GT, Bowman KF, Sterns S, Wagner LJ, Kahana B. Cancer-related health worries and psychological distress among older adult, long-term cancer survivors. *Psychooncology* 2006; 15:306–320.
- Davidson JR, MacLean AW, Brundage MD, Schulze K. Sleep disturbance in cancer patients. *Soc Sci Med* 2002; 54:1309–1321.
- Savard J, Morin CM. Insomnia in the context of cancer: a review of a neglected problem. *J Clin Oncol* 2001; 19:895–908.
- Payne RJ, Hier MP, Kost KM, et al. High prevalence of obstructive sleep apnea among patients with head and neck cancer. *J Otolaryngol* 2005; 34:304–311.
- American Academy of Sleep Medicine. International Classification of Sleep Disorders—Second Edition (ICSD-2); 2005.
- Fortner BV, Stepanski EJ, Wang SC, Kasprovicz S, Durrence HH. Sleep and quality of life in breast cancer patients. *J Pain Symptom Manage* 2002; 24:471–480.
- Chen ML, Yu CT, Yang CH. Sleep disturbances and quality of life in lung cancer patients undergoing chemotherapy. *Lung Cancer* 2008; 62:391–400.
- Liu L, Ancoli-Israel S. Sleep disturbances in cancer. *Psychiatr Ann* 2008; 38:627–634.
- Ancoli-Israel S, Liu L, Marler MR, et al. Fatigue, sleep, and circadian rhythms prior to chemotherapy for breast cancer. *Support Care Cancer* 2006; 14:201–209.
- Miaskowski C, Lee K, Dunn L, et al. Sleep-wake circadian activity rhythm parameters and fatigue in oncology patients before the initiation of radiation therapy. *Cancer Nurs* 2011; 34:255–268.
- Liu L, Rissling M, Natarajan L, et al. The longitudinal relationship between fatigue and sleep in breast cancer patients undergoing chemotherapy. *Sleep* 2012; 35:237–245.
- Savard J, Ivers H, Villa J, Caplette-Gingras A, Morin CM. Natural course of insomnia comorbid with cancer: an 18-month longitudinal study. *J Clin Oncol* 2011; 29:3580–3586.
- Sela RA, Watanabe S, Nekolaichuk CL. Sleep disturbances in palliative cancer patients attending a pain and symptom control clinic. *Palliat Support Care* 2005; 3:23–31.
- Mao JJ, Armstrong K, Bowman MA, Xie SX, Kadakia R, Farrar JT. Symptom burden among cancer survivors: impact of age and comorbidity. *J Am Board Fam Med* 2007; 20:434–443.
- Schroevens MJ, Ranchor AV, Sanderman R. The role of age at the onset of cancer in relation to survivors' long-term adjustment: a controlled comparison over an eight-year period. *Psychooncology* 2004; 13:740–752.
- Stein KD, Syrjala KL, Andrykowski MA. Physical and psychological long-term and late effects of cancer. *Cancer* 2008; 112(suppl 11):2577–2592.
- Anderson KO, Getto CJ, Mendoza TR, et al. Fatigue and sleep disturbance in patients with cancer, patients with clinical depression, and community-dwelling adults. *J Pain Symptom Manage* 2003; 25:307–318.
- Savard J, Villa J, Ivers H, Simard S, Morin CM. Prevalence, natural course, and risk factors of insomnia comorbid with cancer over a 2-month period. *J Clin Oncol* 2009; 27:5233–5239.
- Engstrom CA, Strohl RA, Rose L, Lewandowski L, Stefanek ME. Sleep alterations in cancer patients. *Cancer Nurs* 1999; 22:143–148.
- Hoffman A, Given BA, von Eye A, Given CW, Gift AG. A study on the relationship between fatigue, pain, insomnia, and gender in persons with lung cancer. *Oncol Nurs Forum* 2006; 33:404.
- Hoffman AJ, Given BA, von Eye A, Gift AG, Given CW. Relationships among pain, fatigue, insomnia, and gender in persons with lung cancer. *Oncol Nurs Forum* 2007; 34:785–792.
- Shapiro SL, Bootzin RR, Figueredo AJ, Lopez AM, Schwartz GE. The efficacy of mindfulness-based stress reduction in the treatment of

- sleep disturbance in women with breast cancer: an exploratory study. *J Psychosom Res* 2003; 54:85–91.
24. Shapiro SL, Lopez AM, Schwartz GE, et al. Quality of life and breast cancer: relationship to psychosocial variables. *J Clin Psychol* 2001; 57:501–519.
  25. Mock V, Atkinson A, Barsevick A, et al; National Comprehensive Cancer Network. NCCN practice guidelines for cancer-related fatigue. *Oncology* (Williston Park) 2000; 14:151–161.
  26. Cella D, Davis K, Breitbart W, Curt G; Fatigue Coalition. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. *J Clin Oncol* 2001; 19:3385–3391.
  27. Sateia MJ, Lang BJ. Sleep and cancer: recent developments. *Curr Oncol Rep* 2008; 10:309–318.
  28. Ahluwalia M. Fatigue, pain, and depression among older adults with cancer: still underrecognized and undertreated. *Geriatrics and Aging* 2008; 11:495–501.
  29. Enderlin CA, Coleman EA, Cole C, Richards KC, Hutchins LF, Sherman AC. Sleep across chemotherapy treatment: a growing concern for women older than 50 with breast cancer. *Oncol Nurs Forum* 2010; 37:461–A3.
  30. Winningham ML, Nail LM, Burke MB, et al. Fatigue and the cancer experience: the state of the knowledge. *Oncol Nurs Forum* 1994; 21:23–36.
  31. Berger AM, Mitchell SA. Modifying cancer-related fatigue by optimizing sleep quality. *J Natl Compr Canc Netw* 2008; 6:3–13.
  32. Anderson KO, Getto CJ, Mendoza TR, et al. Fatigue and sleep disturbance in patients with cancer, patients with clinical depression, and community-dwelling adults. *J Pain Symptom Manage* 2003; 25:307–318.
  33. Armstrong TS, Cohen MZ, Eriksen LR, Hickey JV. Symptom clusters in oncology patients and implications for symptom research in people with primary brain tumors. *J Nurs Scholarsh* 2004; 36:197–206.
  34. Dodd MJ, Miaskowski C, Lee KA. Occurrence of symptom clusters. *J Natl Cancer Inst Monogr* 2004; 76–78.
  35. Paice JA. Assessment of symptom clusters in people with cancer. *J Natl Cancer Inst Monogr* 2004; 98–102.
  36. Åhsberg E, Fürst CJ. Dimensions of fatigue during radiotherapy—an application of the Swedish Occupational Fatigue Inventory (SOFI) on cancer patients. *Acta Oncol* 2001; 40:37–43.
  37. Foley KM. The treatment of cancer pain. *N Engl J Med* 1985; 313:84–95.
  38. Twycross RG, Fairfield S. Pain in far-advanced cancer. *Pain* 1982; 14:303–310.
  39. Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. *N Engl J Med* 1994; 330:592–596.
  40. Fleming L, Gillespie S, Espie CA. The development and impact of insomnia on cancer survivors. *Psychooncology* 2010; 19:991–996.
  41. Grond S, Zech D, Diefenbach C, Bischoff A. Prevalence and pattern of symptoms in patients with cancer pain: a prospective evaluation of 1635 cancer patients referred to a pain clinic. *J Pain Symptom Manage* 1994; 9:372–382.
  42. Smith MT, Haythornthwaite JA. How do sleep disturbance and chronic pain inter-relate? Insights from the longitudinal and cognitive-behavioral clinical trials literature. *Sleep Med Rev* 2004; 8:119–132.
  43. Lewin DS, Dahl RE. Importance of sleep in the management of pediatric pain. *J Dev Behav Pediatr* 1999; 20:244–252.
  44. Yue HJ, Guilleminault C. Opioid medication and sleep-disordered breathing. *Med Clin North Am* 2010; 94:435–446.
  45. Teichtahl H, Wang D. Sleep-disordered breathing with chronic opioid use. *Expert Opin Drug Saf* 2007; 6:641–649.
  46. Ancoli-Israel S, Moore PJ, Jones V. The relationship between fatigue and sleep in cancer patients: a review. *Eur J Cancer Care (Engl)* 2001; 10:245–255.
  47. Perlis ML, Giles DE, Buysse DJ, Tu X, Kupfer DJ. Self-reported sleep disturbance as a prodromal symptom in recurrent depression. *J Affect Disord* 1997; 42:209–212.
  48. Stone P, Hardy J, Broadley K, Tookman AJ, Kurowska A, A'Hern R. Fatigue in advanced cancer: a prospective controlled cross-sectional study. *Br J Cancer* 1999; 79:1479–1486.
  49. Cimprich B. Pretreatment symptom distress in women newly diagnosed with breast cancer. *Cancer Nurs* 1999; 22:185–194.
  50. Liu L, Fiorentino L, Natarajan L, et al. Pre-treatment symptom cluster in breast cancer patients is associated with worse sleep, fatigue and depression during chemotherapy. *Psychooncology* 2009; 18:187–194.
  51. Savard J, Hervouet S, Ivers H. Prostate cancer treatments and their side effects are associated with increased insomnia. *Psychooncology* 2013; 22:1381–1388.
  52. Fenlon DR, Corner JL, Haviland J. Menopausal hot flushes after breast cancer. *Eur J Cancer Care (Engl)* 2009; 18:140–148.
  53. Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MR. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. *J Clin Oncol* 2008; 26:971–982.
  54. Kirkbride P, Bezjak A, Pater J, et al. Dexamethasone for the prophylaxis of radiation-induced emesis: a National Cancer Institute of Canada Clinical Trials Group phase III study. *J Clin Oncol* 2000; 18:1960–1966.
  55. Coussens LM, Werb Z. Inflammation and cancer. *Nature* 2002; 420:860–867.
  56. Vgontzas AN, Chrousos GP. Sleep, the hypothalamic-pituitary-adrenal axis, and cytokines: multiple interactions and disturbances in sleep disorders. *Endocrinol Metab Clin North Am* 2002; 31:15–36.
  57. Vgontzas AN, Zoumakis M, Papanicolaou DA, et al. Chronic insomnia is associated with a shift of interleukin-6 and tumor necrosis factor secretion from nighttime to daytime. *Metabolism* 2002; 51:887–892.
  58. Mills PJ, Parker B, Jones V, et al. The effects of standard anthracycline-based chemotherapy on soluble ICAM-1 and vascular endothelial growth factor levels in breast cancer. *Clin Cancer Res* 2004; 10:4998–5003.
  59. Reiter RJ, Tan DX, Korkmaz A, et al. Light at night, chronodisruption, melatonin suppression, and cancer risk: a review. *Crit Rev Oncog* 2007; 13:303–328.
  60. Schernhammer ES, Hankinson SE. Urinary melatonin levels and breast cancer risk. *J Natl Cancer Inst* 2005; 97:1084–1087.
  61. Travis RC, Allen DS, Fentiman IS, Key TJ. Melatonin and breast cancer: a prospective study. *J Natl Cancer Inst* 2004; 96:475–482.
  62. Verkasalo PK, Lillberg K, Stevens RG, et al. Sleep duration and breast cancer: a prospective cohort study. *Cancer Res* 2005; 65:9595–9600.
  63. Wu AH, Wang R, Koh WP, Stanczyk FZ, Lee HP, Yu MC. Sleep duration, melatonin and breast cancer among Chinese women in Singapore. *Carcinogenesis* 2008; 29:1244–1248.
  64. McElroy JA, Newcomb PA, Titus-Ernstoff L, Trentham-Dietz A, Hampton JM, Egan KM. Duration of sleep and breast cancer risk in a large population-based case-control study. *J Sleep Res* 2006; 15:241–249.
  65. Pinheiro SP, Schernhammer ES, Tworoger SS, Michels KB. A prospective study on habitual duration of sleep and incidence of breast cancer in a large cohort of women. *Cancer Res* 2006; 66:5521–5525.
  66. Lie JA, Roessink J, Kjaerheim K. Breast cancer and night work among Norwegian nurses. *Cancer Causes Control* 2006; 17:39–44.
  67. Schernhammer ES, Kroenke CH, Laden F, Hankinson SE. Night work and risk of breast cancer. *Epidemiology* 2006; 17:108–111.
  68. Schernhammer ES, Laden F, Speizer FE, et al. Rotating night shifts and risk of breast cancer in women participating in the Nurses' Health Study. *J Natl Cancer Inst* 2001; 93:1563–1568.
  69. Davis S, Mirick DK, Stevens RG. Night shift work, light at night, and risk of breast cancer. *J Natl Cancer Inst* 2001; 93:1557–1562.
  70. Hansen J. Light at night, shiftwork, and breast cancer risk. *J Natl Cancer Inst* 2001; 93:1513–1515.
  71. Thompson CL, Larkin EK, Patel S, Berger NA, Redline S, Li L. Short duration of sleep increases risk of colorectal adenoma. *Cancer* 2011; 117:841–847.
  72. Degner LF, Sloan JA. Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancer. *J Pain Symptom Manage* 1995; 10:423–431.
  73. Thompson CL, Li L. Association of sleep duration and breast cancer OncotypeDX recurrence score. *Breast Cancer Res Treat* 2012; 134:1291–1295.
  74. Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. *J Clin Sleep Med* 2008; 4:487–504.
  75. Fan HG, Houédé-Tchen N, Yi QL, et al. Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. *J Clin Oncol* 2005; 23:8025–8032.

76. **Ganz PA.** Late effects of cancer and its treatment. *Semin Oncol Nurs* 2001; 17:241–248.
77. **Lee TS, Kilbreath SL, Refshauge KM, Pendlebury SC, Beith JM, Lee MJ.** Quality of life of women treated with radiotherapy for breast cancer. *Support Care Cancer* 2008; 16:399–405.
78. **National Institutes of Health.** National Institutes of Health state of the science conference statement on manifestations and management of chronic insomnia in adults, June 13-15, 2005. *Sleep* 2005; 28:1049–1057.
79. **Smith MT, Huang MI, Manber R.** Cognitive behavior therapy for chronic insomnia occurring within the context of medical and psychiatric disorders. *Clin Psychol Rev* 2005; 25:559–592.
80. **Quesnel C, Savard J, Simard S, Ivers H, Morin CM.** Efficacy of cognitive-behavioral therapy for insomnia in women treated for nonmetastatic breast cancer. *J Consult Clin Psychol* 2003; 71:189–200.
81. **Savard J, Simard S, Ivers H, Morin CM.** Randomized study on the efficacy of cognitive-behavioral therapy for insomnia secondary to breast cancer, part I: sleep and psychological effects. *J Clin Oncol* 2005; 23:6083–6096.
82. **Berger AM, Kuhn BR, Farr LA, et al.** Behavioral therapy intervention trial to improve sleep quality and cancer-related fatigue. *Psychooncology* 2009; 18:634–646.
83. **Espie CA, Fleming L, Cassidy J, et al.** Randomized controlled clinical effectiveness trial of cognitive behavior therapy compared with treatment as usual for persistent insomnia in patients with cancer. *J Clin Oncol* 2008; 26:4651–4658.
84. **National Institutes of Health.** National Institutes of Health state of the science conference statement on manifestations and management of chronic insomnia in adults, June 13-15, 2005. *Sleep* 2005; 28:1049–1057.
85. **Savard J, Villa J, Simard S, Ivers H, Morin CM.** Feasibility of a self-help treatment for insomnia comorbid with cancer. *Psychooncology* 2011; 20:1013–1019.
86. **Derogatis LR, Feldstein M, Morrow G, et al.** A survey of psychotropic drug prescriptions in an oncology population. *Cancer* 1979; 44:1919–1929.
87. **Stiefel FC, Kornblith AB, Holland JC.** Changes in the prescription patterns of psychotropic drugs for cancer patients during a 10-year period. *Cancer* 1990; 65:1048–1053.
88. **Minton O, Richardson A, Sharpe M, Hotopf M, Stone P.** A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. *J Natl Cancer Inst* 2008; 100:1155–1166.
89. **Minton O, Stone P, Richardson A, Sharpe M, Hotopf M.** Drug therapy for the management of cancer-related fatigue. *Cochrane Database Syst Rev* 2008; CD006704.
90. **Krystal AD, Walsh JK, Laska E, et al.** Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. *Sleep* 2003; 26:793–799.
91. **Liu J, Wang LN.** Ramelteon in the treatment of chronic insomnia: systematic review and meta-analysis. *Int J Clin Pract* 2012; 66:867–873.
92. **Cankurtaran ES, Ozalp E, Soygur H, Akbiyik DI, Turhan L, Alkis N.** Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. *Support Care Cancer* 2008; 16:1291–1298.
93. **Palesh OG, Mustian KM, Peppone LJ, et al.** Impact of paroxetine on sleep problems in 426 cancer patients receiving chemotherapy: a trial from the University of Rochester Cancer Center Community Clinical Oncology Program. *Sleep Med* 2012; 13:1184–1190.

---

**ADDRESS:** Harneet Walia, MD, Center for Sleep Disorders, FA20, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: [waliah@ccf.org](mailto:waliah@ccf.org)